Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration
- PMID: 38876134
- DOI: 10.1016/S0140-6736(24)00915-2
Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration
Conflict of interest statement
GSY is currently funded by grants from the National Eye Institute of the National Institute of Health. He has received biostatistics consultation fees from Ziemmer Ophthalmic Systems and has received fees for services as a member of the data safety monitoring committee for Advarra. BLVB has received an honorarium for being an organiser and presenter at the 2023 Real World Data Symposium.
Comment on
-
Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.Lancet. 2024 Jul 6;404(10447):44-54. doi: 10.1016/S0140-6736(24)00687-1. Epub 2024 Jun 11. Lancet. 2024. PMID: 38876132 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical